Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2248367/is-adicet-bio-acet-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2248367
Apr 01, 2024 - Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
0
Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma
https://seekingalpha.com/news/4087581-bristol-myers-2seventy-bio-receive-fda-approval-for-abecma-to-treat-multiple-myeloma?source=feed_sector_healthcare
Apr 05, 2024 - The CAR T therapy Abecma has been approved for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy. Read more here.
0
Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2251973/wall-street-analysts-see-a-218-92-upside-in-annovis-bio-anvs-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2251973
Apr 08, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
0
Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
https://seekingalpha.com/article/4683358-bruker-offers-upside-with-key-enabling-technologies-for-future-bio-pharma-research?source=feed_all_articles
Apr 11, 2024 - Bruker offers growth at reasonable price for investors and is well-positioned for healthy revenue growth in 2024. Find out why BRKR stock is a Buy.
0
Oppenheimer starts Q32 Bio at outperform, cites lead asset
https://seekingalpha.com/news/4088992-oppenheimer-starts-q32-bio-at-outperform-cites-lead-asset?source=feed_sector_healthcare
Apr 11, 2024 - Oppenheimer started coverage of Q32 Bio (QTTB) with an outperform rating, citing the market potential of the company’s lead drug asset, bempikibart. Read more here.
0
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
https://www.zacks.com/stock/news/2254517/is-entera-bio-entx-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2254517
Apr 12, 2024 - Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year.
0
Better Buy: Bluebird Bio Vs. Novavax
https://www.fool.com/investing/2024/04/13/better-buy-bluebird-bio-vs-novavax/?source=iedfolrf0000001
Apr 13, 2024 - Who wins this face-to-face between two beaten-down biotechs?
0
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
0
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
https://www.zacks.com/stock/news/2257849/bio-rad-laboratories-bio-to-post-q1-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257849
Apr 18, 2024 - The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
0
Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today
https://www.zacks.com/stock/news/2258103/why-the-market-dipped-but-entera-bio-ltd-entx-gained-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2258103
Apr 18, 2024 - In the closing of the recent trading day, Entera Bio Ltd. (ENTX) stood at $2.24, denoting a +0.9% change from the preceding trading day.
0